Clinical Research Directory
Browse clinical research sites, groups, and studies.
Finerenone Therapy for Pediatric HSPN With Mild Proteinuria
Sponsor: Capital Institute of Pediatrics, China
Summary
Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease. Currently, the treatment for children with mild proteinuria HSPN mainly involves ACEI/ARB, but long-term use of these drugs can lead to an increase in aldosterone levels, affecting therapeutic efficacy. Finerenone can improve vascular endothelial cell dysfunction and renal tissue inflammation and fibrosis, and reduce urinary protein in patients with glomerular diseases. This study intends to conduct an exploratory randomized controlled clinical trial of finerenone in children with HSPN accompanied by a small amount of proteinuria to evaluate the efficacy and safety of finerenone treatment.
Official title: The Randomized Controlled Trial of Finerenone Therapy for Pediatric Hennoch Scholein Nephritis With Mild Proteinuria
Key Details
Gender
All
Age Range
3 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
116
Start Date
2025-06-13
Completion Date
2028-04-30
Last Updated
2026-01-07
Healthy Volunteers
No
Conditions
Interventions
ACEI / ARB+finerenone
In the finerenone group, finerenone was administered orally on the basis of combined oral ACEI/ARB, with the dose calculated based on body surface area, once a day for 3 months.
ACEI/ARB
The control group was only given oral ACEI/ARB for 3 months.
Locations (1)
Capital Center for Children's Health,Capital Medical University
Beijing, Beijing Municipality, China